The OrganaBio Blog

The Supply Brain

Addressing supply chain challenges in cell and gene therapy

Who We Are

OrganaBio was founded in 2018 by scientists and business leaders motivated to bring next generation regenerative medicine therapies to market. Since then, we have assembled a team of 16 industry veterans, from scientists and engineers with years of bioprocess and therapeutic development experience to those versed in Quality Assurance, Quality Control, Regulatory Affairs and successful business-building. Combined, we have over two centuries of experience in all areas necessary for success in regenerative medicine! Our team is passionate about expediting the development of novel cell and gene therapies, ultimately improving quality of life and/or saving lives for many. We truly believe that regenerative medicine is the future of medicine, and we work relentlessly to help our customers and partners bring their therapies to market.

Through our many years in the industry, the OrganaBio team recognizes that supply chain limitations, such as the availability of well-characterized, cGMP-compatible cellular raw materials and access to cGMP manufacturing infrastructure, are a severely limiting factor for the development and sustained success of therapies. Companies both big and small are eager to bring potentially life-saving technologies to the patients who need them most. The path to clinic is long and filled with costly, time intensive roadblocks, many of which slow or even completely halt the development of therapies so desperately needed by patients. That’s where OrganaBio comes in. We work to empower these companies to move forward with their treatments by means of supplying them with the tools they need to overcome the challenges of development and clinical scale-up. That’s why our company’s approach to the regenerative medicine market is grounded in supply chain control, redundancy and quality. To that end, we are offering the industry a selection of perinatal tissue-derived cells, including mesenchymal stem/stromal cells and immune cells such as NK and T cells. In addition, we will soon be opening our first cGMP multi-tenant facility (which we call Option C) to provide much-needed, flexible manufacturing solutions to therapeutic developers.
OrganaBio puts its resources to work for our customers and partners; We pave a smoother path from the idea to the patient. So, what really answers the question “Who are we?” is simple: We are people who empower. We are excited to be a part of this rapidly growing industry and are eager to hear how we can help you bring your therapies to market. Please contact us to learn more.

Priya Baraniak, Ph.D.

Priya Baraniak, Ph.D.

Dr. Baraniak is a proven strategic thinker, problem solver and leader who brings 20 years of expertise in stem cells and tissue engineering, coupled with a keen business acumen, to OrganaBio. Dr. Baraniak has published multiple peer-reviewed papers and book chapters on the use of stem cells and biomaterials in cardiac repair and regeneration and is routinely invited to speak at conferences.